Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease, BMJ Open Respir Res, vol.4, p.212, 2017. ,
Transbronchial cryobiopsy in the diagnosis of interstitial lung disease: a cool new approach, Respirology, vol.19, pp.623-624, 2014. ,
Idiopathic pulmonary fibrosis, Lancet, vol.389, pp.1941-1952, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01600144
Presentation, diagnosis and clinical course of the spectrum of progressive fibrosing interstitial lung diseases, Eur Respir Rev, vol.26, p.180076, 2017. ,
An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias, Am J Respir Crit Care Med, vol.188, pp.733-748, 2013. ,
An Official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline, Am J Respir Crit Care Med, vol.192, pp.3-19, 2015. ,
Pilot study of pirfenidone in pulmonary fibrosis with anti-myeloperoxydase antibodies (PIRFENIVAS), 2018. ,
Esbriet® Summary of Product Characteristics, 2018. ,
Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials, Respir Med, vol.113, pp.74-79, 2016. ,
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am J Respir Crit Care Med, vol.183, pp.788-824, 2011. ,
Current approaches to the management of idiopathic pulmonary fibrosis, Respir Med, vol.129, pp.24-30, 2017. ,
Antifibrotic therapy in idiopathic pulmonary fibrosis, Ulster Med J, vol.86, p.73, 2017. ,
,
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis, N Engl J Med, vol.365, pp.1079-1087, 2011. ,
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis, N Engl J Med, vol.370, pp.2071-2082, 2014. ,
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med, vol.370, pp.2083-2092, 2014. ,
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy, Cancer Res, vol.68, pp.4774-4782, 2008. ,
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis, Eur Respir J, vol.45, pp.1434-1445, 2015. ,
Nintedanib: from discovery to the clinic, J Med Chem, vol.58, pp.1053-1063, 2015. ,
Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to connective tissue disease-associated interstitial lung disease, Eur Respir J, vol.50, p.903, 2017. ,
Nintedanib for the treatment of idiopathic pulmonary fibrosis, Expert Opin Pharmacother, vol.19, pp.167-175, 2018. ,
, European Medicines Agency. Science Medicines Health. OFEV® (nintedanib, 2017.
Pirfenidone for Progressive Fibrotic Sarcoidosis (PirFS), 2017. ,
The multifaceted role of pirfenidone and its novel targets, Fibrogenesis Tissue Repair, vol.3, p.16, 2010. ,
What's in a name? That which we call IPF, by any other name would act the same, Eur Respir J, vol.51, p.1800692, 2018. ,
Esbriet® US prescribing information, 2017. ,
, Esbriet® ( pirfenidone) authorisation details, European Medicines Agency. Science Medicines Health, 2018.
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, Lancet, vol.377, pp.1760-1769, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00873255
Pharmaceuticals and Medical Devices Agency, Japan. Pirespa® ( pirfenidone) authorisation details. www.pmda.go.jp/files/000153687.pdf. Date last updated: Sept 16, 2008. ,
Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function, Lung, vol.188, pp.143-149, 2010. ,
Nonspecific interstitial pneumonia: survival is influenced by the underlying cause, Eur Respir J, vol.45, pp.746-755, 2015. ,
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project, Am J Respir Crit Care Med, vol.177, pp.1338-1347, 2008. ,
Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumonia, Respirology, vol.23, pp.1032-1040, 2018. ,
Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia, Eur Respir J, vol.25, pp.528-533, 2005. ,
Nonspecific interstitial pneumonia: what is the optimal approach to management?, Semin Respir Crit Care Med, vol.37, pp.378-394, 2016. ,
Factors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study, Respir Res, vol.18, p.204, 2017. ,
Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia, Sarcoidosis Vasc Diffuse Lung Dis, vol.26, pp.132-138, 2009. ,
Prevalence and prognosis of unclassifiable interstitial lung disease, Eur Respir J, vol.42, pp.750-757, 2013. ,
Clinico-radio-pathological characteristics of unclassifiable idiopathic interstitial pneumonias, Respir Investig, vol.56, pp.40-47, 2018. ,
, European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, Am J Respir Crit Care Med, vol.165, pp.277-304, 2002.
Practical management of respiratory comorbidities in patients with rheumatoid arthritis, Rheumatol Ther, vol.4, pp.309-332, 2017. ,
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review, Ther Adv Musculoskelet Dis, vol.7, pp.247-267, 2015. ,
Rheumatoid arthritis-associated lung disease, Eur Respir Rev, vol.24, pp.1-16, 2015. ,
Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre, Rheumatology (Oxford), vol.56, pp.1348-1357, 2017. ,
Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients, Semin Arthritis Rheum, vol.48, pp.22-27, 2018. ,
Phase ll study of pirfenidone in patients with RAILD, 2017. ,
Management of systemic-sclerosis-associated interstitial lung disease, Rheum Dis Clin North Am, vol.41, pp.439-457, 2015. ,
Cyclophosphamide versus placebo in scleroderma lung disease, N Engl J Med, vol.354, pp.2655-2666, 2006. ,
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease, Am J Respir Crit Care Med, vol.176, pp.1026-1034, 2007. ,
A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma, Clin Rheumatol, vol.30, pp.223-229, 2011. ,
,
Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease, J Rheumatol, vol.40, pp.640-646, 2013. ,
Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis, Pulm Med, vol.2012, p.143637, 2012. ,
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial, Lancet Respir Med, vol.4, pp.708-719, 2016. ,
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study, Rheumatology (Oxford), vol.49, pp.271-280, 2010. ,
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group, Ann Rheum Dis, vol.74, pp.1188-1194, 2015. ,
Rituximab in autoimmune connective tissue disease-associated interstitial lung disease, Rheumatology (Oxford), vol.55, pp.1318-1324, 2016. ,
Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis, Clin Exp Rheumatol, vol.30, pp.17-22, 2012. ,
Rituximab versus cyclophosphamide in connective tissue disease-ILD (RECITAL), 2017. ,
An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial, J Rheumatol, vol.43, pp.1672-1679, 2016. ,
Current treatment of patients with non-IPF progressive fibrosing interstitial lung disease, Am J Respir Crit Care Med, vol.197, p.4273, 2018. ,
Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease, Sarcoidosis Vasc Diffuse Lung Dis, vol.31, pp.235-238, 2014. ,
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease, Ann Rheum Dis, vol.60, pp.577-584, 2001. ,
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry, Ann Rheum Dis, vol.63, pp.974-981, 2004. ,
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study, Blood, vol.110, pp.1388-1396, 2007. ,
Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial, Lancet, vol.378, pp.498-506, 2011. ,
Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis, Rheumatology (Oxford), vol.54, pp.2126-2133, 2015. ,
Recent advances in connective tissue disease related interstitial lung disease, Expert Rev Respir Med, vol.11, pp.591-603, 2017. ,
Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial, JAMA, vol.311, pp.2490-2498, 2014. ,
Myeloablative autologous stem-cell transplantation for severe scleroderma, N Engl J Med, vol.378, pp.35-47, 2018. ,
The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes, Chest, vol.148, pp.1034-1042, 2015. ,
Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis, Chest, vol.144, pp.1644-1651, 2013. ,
Interstitial lung disease, 2016. ,
Treatment and monitoring of hypersensitivity pneumonitis, Expert Rev Clin Immunol, vol.12, pp.953-962, 2016. ,
Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis, ERJ Open Res, vol.3, pp.16-02017, 2017. ,
Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis, Chest, vol.151, pp.619-625, 2017. ,
, Lancet, vol.383, pp.1155-1167, 2014.
Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations, Curr Opin Rheumatol, vol.30, pp.243-248, 2018. ,
Leflunomide for chronic sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, vol.21, pp.43-48, 2004. ,
Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis, Eur Respir J, vol.38, pp.1145-1150, 2011. ,
Refractory pulmonary sarcoidosis -proposal of a definition and recommendations for the diagnostic and therapeutic approach, Clin Pulm Med, vol.23, pp.67-75, 2016. ,
Methotrexate vs azathioprine in second-line therapy of sarcoidosis, Chest, vol.144, pp.805-812, 2013. ,
Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study, Respiration, vol.86, pp.376-383, 2013. ,
Efficacy of mycophenolate mofetil in sarcoidosis, Respir Med, vol.108, pp.1663-1669, 2014. ,
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement, Am J Respir Crit Care Med, vol.174, pp.795-802, 2006. ,
Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes, Ann Am Thorac Soc, vol.10, pp.362-370, 2013. ,
,
A systematic review of occupational exposure to coal dust and the risk of interstitial lung diseases, Eur Clin Respir J, vol.4, p.1264711, 2017. ,
Coal mine dust lung disease in the modern era, Respirology, vol.22, pp.662-670, 2017. ,
Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?), Curr Opin Pulm Med, vol.23, pp.418-425, 2017. ,
Scleroderma lung disease, Eur Respir Rev, vol.22, pp.6-19, 2013. ,
Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?, Arthritis Rheumatol, vol.66, pp.1967-1978, 2014. ,
, A trial to compare nintedanib with placebo for patients with scleroderma-related lung fibrosis, 2018.
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS), Clin Exp Rheumatol, vol.35, pp.75-81, 2017. ,
, Efficacy and safety of nintedanib in patients with progressive fibrosing interstitial lung disease, 2018.
Nintedanib in lung transplant recipients with bronchiolitis obliterans syndrome grade 1-2 (INFINITx-BOS, 2018. ,
Exploring efficacy and safety of oral pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) -a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial, BMC Pulm Med, vol.17, p.122, 2017. ,
Study of efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis, 2017. ,
97 A study of pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease, Pirfenidone in the chronic hypersensitivity pneumonitis treatment (Picheon, 2015. ,
Pirfenidone in progressive interstitial lung disease associated with clinically amyopathic dermatomyositis, 2016. ,
Date last accessed, BOS, a European multi-center study, 2016. ,
Scleroderma Lung Study III -Combining Pirfenidone With Mycophenolate (SLSIII). https:// clinicaltrials.gov/ct2/show/NCT03221257 Date last updated: Sept 10, 2018. ,
Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis, J Pharmacol Exp Ther, vol.349, pp.209-220, 2014. ,
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis, Ann Rheum Dis, vol.75, pp.883-890, 2016. ,